Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

68.83

Margin Of Safety %

Put/Call OI Ratio

0.4

EPS Next Q Diff

0.01

EPS Last/This Y

0.06

EPS This/Next Y

0.19

Price

2.47

Target Price

11.25

Analyst Recom

1.4

Performance Q

-18.75

Relative Volume

0.72

Beta

0.28

Ticker: IBRX



22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-20IBRX2.750.394.77198396
2025-03-21IBRX2.720.391.04198568
2025-03-24IBRX2.840.360.71165417
2025-03-25IBRX2.750.361.69167005
2025-03-26IBRX2.770.370.18168595
2025-03-27IBRX3.340.370.42169956
2025-03-28IBRX3.130.370.66174611
2025-03-31IBRX30.371.04175893
2025-04-01IBRX2.950.380.75177939
2025-04-02IBRX3.040.381.07179246
2025-04-03IBRX2.970.390.30179946
2025-04-04IBRX2.830.390.79180555
2025-04-07IBRX2.710.420.36194634
2025-04-08IBRX2.430.411.65196415
2025-04-09IBRX2.60.440.08202835
2025-04-10IBRX2.450.430.28203543
2025-04-11IBRX2.620.430.35204909
2025-04-14IBRX2.880.430.19206228
2025-04-15IBRX2.770.421.36210246
2025-04-16IBRX2.490.400.51209151
2025-04-17IBRX2.470.400.72209096
2025-04-18IBRX2.470.400.69209096
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1



22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-20IBRX2.75- 40.2-0.52
2025-03-21IBRX2.72- 41.8-0.52
2025-03-24IBRX2.85- 29.0-0.52
2025-03-25IBRX2.74- 47.6-0.52
2025-03-26IBRX2.78- 36.4-0.52
2025-03-27IBRX3.34- -3.0-0.52
2025-03-28IBRX3.14- 53.6-0.52
2025-03-31IBRX3.01- 48.4-0.52
2025-04-01IBRX2.96- 43.0-0.52
2025-04-02IBRX3.05- 33.0-0.52
2025-04-03IBRX2.97- 45.1-0.52
2025-04-04IBRX2.83- 49.5-0.52
2025-04-07IBRX2.71- 49.2-0.52
2025-04-08IBRX2.42- 62.7-0.52
2025-04-09IBRX2.60- 25.5-0.52
2025-04-10IBRX2.45- 51.2-0.52
2025-04-11IBRX2.62- 25.9-0.52
2025-04-14IBRX2.89- 18.7-0.52
2025-04-15IBRX2.78- 47.6-0.52
2025-04-16IBRX2.48- 61.9-0.52
2025-04-17IBRX2.47- 40.3-0.53
2025-04-18IBRX2.47- 39.5-0.53
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1



22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-20IBRX0.0018.3268.63
2025-03-21IBRX0.0018.3268.63
2025-03-24IBRX0.0018.2368.63
2025-03-25IBRX0.0018.2368.63
2025-03-26IBRX0.0018.2367.07
2025-03-27IBRX0.0018.2367.07
2025-03-28IBRX0.0018.2367.07
2025-03-31IBRX0.0018.1167.07
2025-04-01IBRX0.0018.1167.07
2025-04-02IBRX0.0018.1167.07
2025-04-03IBRX0.0018.1167.07
2025-04-04IBRX0.0018.1167.07
2025-04-07IBRX0.0018.1167.07
2025-04-08IBRX0.0018.1167.07
2025-04-09IBRX0.0018.1167.07
2025-04-10IBRX0.0018.1171.17
2025-04-11IBRX0.0018.1171.17
2025-04-14IBRX0.0017.4368.83
2025-04-15IBRX0.0017.4368.83
2025-04-16IBRX0.0017.4368.83
2025-04-17IBRX0.0017.4368.83
2025-04-18IBRX0.0017.4368.83
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS​

-0.15

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

17.43

Beta

0.28

Average Sales Estimate Current Quarter

17

Average Sales Estimate Next Quarter

22

Fair Value

Quality Score

24

Growth Score

58

Sentiment Score

15

Actual DrawDown %

94

Max Drawdown 5-Year %

Target Price

11.25

P/E

Forward P/E

PEG

P/S

147.88

P/B

P/Free Cash Flow

EPS

-0.63

Average EPS Est. Cur. Y​

-0.53

EPS Next Y. (Est.)

-0.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2804.77

Relative Volume

0.72

Return on Equity vs Sector %

64.6

Return on Equity vs Industry %

78

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

39.5
ImmunityBio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 680
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today
news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance
stock history IBRX – ImmunityBio, Inc. invest stock market
stock prices IBRX premarket after hours
ticker IBRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About